Best projectsinknowledge podcasts we could find (Updated June 2017)
Related podcasts: Pik Bevacizumab Science Ca125 Disease Recurrence Treatment Duration Single-agent Therapy First-line Treatment Re-treatment Patient Monitoring Molecular Profiling Tumor Sensitivity Assays Dose Reduction Toxicities Rebound Maintenance  
Projectsinknowledge public [search 0]
show episodes
 
P
Personalizing Treatment and Managing Patient Concerns
 
Drs. Bradley Monk and Robert Coleman examine practical issues to consider in managing toxicities associated with antiangiogenic agents: dealing with side effects of first-line versus palliative treatment, the possibility of dose reduction to alleviate toxicities, risk factors for catastrophic side effects such as RPLS and GI perforation, and whether patients with serious side effects can be re-treated when these events have resolved. They also address the role of sensitivity tests and molecu ...
 
U
Using Targeted Therapies in a Real-World Setting
 
In this engaging podcast, Drs. Bradley Monk and Robert Burger discuss important practical issues regarding the use of antiangiogenic therapy to treat epithelial ovarian cancer, including the possible value of targeted agents as maintenance therapy, the correct dosage and duration of targeted therapy, and the role of CA125 in determining tumor progression with a biologic agent
 
Loading …
show series
 
P
Personalizing Treatment and Managing Patient Concerns
 
The experts discuss the current and future practical uses of tumor sensitivity assays and molecular profiling.
 
P
Personalizing Treatment and Managing Patient Concerns
 
The experts discuss the management of bevacizumab toxicities in first-line vs palliative treatment and the need to monitor for serious side effects.
 
U
Using Targeted Therapies in a Real-World Setting
 
The experts discuss the continued use of bevacizumab and/or other targeted agents in treating recurrent disease.
 
U
Using Targeted Therapies in a Real-World Setting
 
Two experts discuss the practical use of bevacizumab in epithelial ovarian cancer and the particular benefit observed in this cancer compared to activity in solid tumors.
 
Speed
Series preference
1x
1x
Volume
100%
/

Google login Twitter login Classic login